Abstract
Dithiocarbamates and their complexes with transition metals have been used as common pesticides, vulcanizing or analytical agents for decades. These compounds are one of the most reported inhibitors of nuclear factor-κB (NF-κB) signaling cascade. Recently, it has been found that dithiocarbamates are very potent inhibitors of proteasome. NF-κB plays a central role in the immune system and is described as a major actor in many of human cancers mainly because of its protective effects against apoptosis. Molecular mechanisms involved in regulation and function of NF-κB pathway have been elucidated recently. In particular, pivotal zinc containing proteins that alter NF-κB signal transduction were recognized. Additionally, proteasome system was found to be a key player in NF-κB pathway and is an attractive target for anticancer drug development. Collectively, the capability of dithiocarbamates to inhibit NF-κB and proteasome makes these compounds promising anticancer agents. This review focuses on the biological activity of dithiocarbamate coordination compounds with regard to their possible molecular targets in NF-κB signaling and proteasome (JAMM domain proteins). Future research should aim to find the most suitable dithiocarbamate coordination compounds for treatment of cancer and other diseases.
Keywords: Disulfiram, Diethyldithiocarbamate (DDTC), Pyrrolidinedithiocarbamate (PDTC), Metal dithiocarbamates, NF-κB, Proteasome, JAMM
Current Pharmaceutical Design
Title: Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Volume: 13 Issue: 30
Author(s): B. Cvek and Z. Dvorak
Affiliation:
Keywords: Disulfiram, Diethyldithiocarbamate (DDTC), Pyrrolidinedithiocarbamate (PDTC), Metal dithiocarbamates, NF-κB, Proteasome, JAMM
Abstract: Dithiocarbamates and their complexes with transition metals have been used as common pesticides, vulcanizing or analytical agents for decades. These compounds are one of the most reported inhibitors of nuclear factor-κB (NF-κB) signaling cascade. Recently, it has been found that dithiocarbamates are very potent inhibitors of proteasome. NF-κB plays a central role in the immune system and is described as a major actor in many of human cancers mainly because of its protective effects against apoptosis. Molecular mechanisms involved in regulation and function of NF-κB pathway have been elucidated recently. In particular, pivotal zinc containing proteins that alter NF-κB signal transduction were recognized. Additionally, proteasome system was found to be a key player in NF-κB pathway and is an attractive target for anticancer drug development. Collectively, the capability of dithiocarbamates to inhibit NF-κB and proteasome makes these compounds promising anticancer agents. This review focuses on the biological activity of dithiocarbamate coordination compounds with regard to their possible molecular targets in NF-κB signaling and proteasome (JAMM domain proteins). Future research should aim to find the most suitable dithiocarbamate coordination compounds for treatment of cancer and other diseases.
Export Options
About this article
Cite this article as:
Cvek B. and Dvorak Z., Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals, Current Pharmaceutical Design 2007; 13 (30) . https://dx.doi.org/10.2174/138161207782110390
DOI https://dx.doi.org/10.2174/138161207782110390 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Cardioprotective Activities of some Indian Spices: An Insight into Pharmacology and Phytochemical Investigation
Current Traditional Medicine Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Vasopressin Receptor Antagonists in Heart Failure
Recent Patents on Cardiovascular Drug Discovery From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Management of Severe Abdominal Infections
Recent Patents on Anti-Infective Drug Discovery Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Vascular effects of flavonoids
Current Medicinal Chemistry Should Percutaneous Coronary Intervention be the Standard Treatment Strategy for Significant Coronary Artery Disease in all Octogenarians?
Current Cardiology Reviews Therapeutic Assessment of Crystalloid Fluid Resuscitation in Experimental Military Injury
Current Pharmaceutical Biotechnology Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Turnover Studies on Cardiac Natriuretic Peptides: Methodological,Pathophysiological and Therapeutical Considerations.
Current Drug Metabolism A Study of the Relaxed Mechanisms Induced by Novokinin in the Isolated Porcine Coronary Artery Ring Segments
Protein & Peptide Letters Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design